3-(2-methyl-1H-imidazol-1-yl)propan-1-ol | 22159-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-methyl-1H-imidazol-1-yl)propan-1-ol
• 英文别名: 1-(3-hydroxypropyl)-2-methylimidazole；2-methyl-1-(3-hydroxypropyl)imidazole；3-(2-methylimidazol-1-yl)propan-1-ol
• CAS: 22159-27-9
• 化学式: C₇H₁₂N₂O
• mdl: MFCD12186756
• 分子量: 140.185
• InChiKey: YAWYZRXSWDINCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  3-(2-methyl-1H-imidazol-1-yl)propan-1-ol 、 4-(4-氯-2-氟苯基氨基)-7-羟基-6-甲氧基喹唑啉 在 三苯基膦 、 偶氮二甲酸二乙酯 、 盐酸 作用下， 以 二氯甲烷 、 乙醚 为溶剂， 反应 5.0h， 以32%的产率得到4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(2-methylimidazol-1-yl)propoxy)quinazoline hydrochloride
  参考文献：
  名称：

  Chemical compounds

  摘要：

  该发明涉及以下结构的喹唑啉衍生物：[其中：Y1代表—O—、—S—、—CH2—、—SO—、—SO2—、—NR5CO—、—CONR6—、—SO2NR7—、—NR8SO2—或—NR9—（其中R5、R6、R8和R9分别独立代表氢、烷基或烷氧基烷基）；R1代表氢、羟基、卤素、硝基、三氟甲基、氰基、烷基、烷氧基、烷硫基、氨基或烷基氨基。R2代表氢、羟基、卤素、烷基、烷氧基、三氟甲基、氰基、氨基或硝基；m为1到5的整数；R3代表羟基、卤素、烷基、烷氧基、烷酰氧基、三氟甲基、氰基、氨基或硝基；R4代表一个或含有一个可选择取代的吡啶酮、苯基或芳香杂环基团的基团]及其盐；其制备方法以及含有I式化合物或其药学上可接受的盐作为活性成分的药物组合物。I式化合物及其药学上可接受的盐抑制VEGF的作用，这在治疗包括癌症和类风湿关节炎在内的多种疾病状态中具有价值。

  公开号：

  US06362336B1
• 作为产物：
  描述：

  1,3-二氧杂环己烷-2-酮 、 2-甲基咪唑 以 甲苯 为溶剂， 反应 5.0h， 以76%的产率得到3-(2-methyl-1H-imidazol-1-yl)propan-1-ol
  参考文献：
  名称：

  用碳酸二烷基酯和碳酸亚烷基酯对咪唑进行 N-烷基化

  摘要：

  咪唑与一系列碳酸二烷基酯和碳酸亚烷基酯的反应以高产率提供相应的 N-烷基-和 N-(羟烷基)咪唑。碳酸二烷基酯的反应性按碳酸二甲酯 > 二乙基 > 碳酸二丁酯的顺序降低。碳酸亚乙酯是比碳酸三亚甲基酯更有效的烷基化剂。通过DFT量子化学计算在B3LYP/6-311++G(d,p)理论水平上研究了咪唑与碳酸二甲酯和碳酸亚乙酯的烷基化机理。

  DOI：

  10.1134/s1070428020120052

文献信息

• Nitrogen heterocycles
  申请人：Imperial Chemical Industries, PLC

  公开号：US04570000A1

  公开（公告）日：1986-02-11

  The invention relates to nitrogen heterocycles which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I:- ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-lOC alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.3 --E--W is which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O, S, SO, SO.sub.2 or NR.sup.4 in which R.sup.4 is H or 1-6C alkyl, R.sup.3 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.3 and R.sup.4 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R.sup.2 is H and R.sup.1 is H, 1-1OC alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-1OC aryl, 7-11C aralkyl or 7-11C aroyl; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8C alkylene into which is optionally inserted one or two groups; ring Y is a heterocyclic ring described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及一种氮杂环化合物，它们是组胺H-2拮抗剂并且抑制胃酸分泌。根据本发明，提供了式I的鸟氨酸衍生物：- ##STR1##其中R1和R2相同或不同，是氢或1-10C烷基，3-8C环烷基或4-14C环烷基烷基，每个烷基，环烷基或环烷基烷基可选地携带一个或多个F，Cl或Br原子，前提是R1和R2中的一个被卤素取代，或者R2是氢，R1是R3-E-W，W是2-6C烷基，可选地被1或2个1-4C烷基取代，E是O，S，SO，SO.sub.2或NR4，其中R4是H或1-6C烷基，R3是H或1-6C烷基，可选地被1或2个1-4C烷基取代，或者R3和R4连接成吡咯烷，哌嗪，吗啉，哌嗪或N-甲基哌嗪环，或者R2是H，R1是H，1-10C烷基，3-8C环烷基，4-14C环烷基烷基，3-6C烯基，3-6C炔基，1-6C酰基，6-10C芳基，7-11C芳基烷基或7-11C芳酰基；环X是规定在说明书中的杂环；A是苯基或5-7C环烷基，或者是可选地插入一个或两个基团的1-8C烷基；环Y是说明书中描述的杂环；以及其药学上可接受的酸加成盐。还描述了制造工艺和制药组合物。
• [EN] QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE L'ANGIOGENESE
  申请人：ASTRAZENECA UK LTD

  公开号：WO2000047212A1

  公开（公告）日：2000-08-17

  The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C¿1-3?alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR?3R4¿ (wherein R?3 and R4¿, which may be the same or different, each represents hydrogen or C¿1-3?alkyl), or R?5X1¿- (wherein X?1 and R5¿ are as defined herein; R1 represents hydrogen, oxo, halogeno, hydroxy, C¿1-4?alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group R?56X10¿ (wherein X?10 and R56¿ are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及使用式(I)的化合物，其中环C是一个含有1-3个杂原子（独立选择自O、N和S）的8、9、10、12或13元的双环或三环基团；Z是-O-、-NH-、-S-、-CH2-或直接键；n为0-5；m为0-3；R2代表氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、-NR3R4（其中R3和R4，可能相同或不同，每个代表氢或C1-3烷基），或R5X1-（其中X1和R5如上定义）；R1代表氢、氧代、卤代、羟基、C1-4烷氧基、C1-4烷基、C1-4烷氧甲基、C1-4烷酰基、C1-4卤代烷基、氰基、氨基、C2-5烯基、C2-5炔基、C1-3烷酰氧基、硝基、C1-4烷酰胺基、C1-4烷氧羰基、C1-4烷基硫基、C1-4烷基亚砜基、C1-4烷基磺酰基、氨基甲酰基、N-C1-4烷基氨基甲酰基、N,N-二(C1-4烷基)氨基甲酰基、氨基磺酰基、N-C1-4烷基氨基磺酰基、N,N-二(C1-4烷基)氨基磺酰基、N-(C1-4烷基磺酰基)氨基、N-(C1-4烷基磺酰基)-N-(C1-4烷基)氨基、N,N-二(C1-4烷基磺酰基)氨基、与两个环C碳原子连接的C3-7烷基链、C1-4烷酰胺基C1-4烷基、羧基或R56X10基团（其中X10和R56如上定义）；以及其盐，在制备用于在温血动物中产生抗血管生成和/或血管通透性降低效应的药物中使用，制备这种化合物的过程，包含式(I)的化合物或其药学上可接受的盐作为活性成分的制药组合物和式(I)的化合物。式(I)的化合物及其药学上可接受的盐抑制VEGF的效果，这是治疗包括癌症和类风湿性关节炎在内的许多疾病状态的有价值的属性。
• Quinazoline derivatives as angiogenesis inhibitors
  申请人：Stokes SE Elaine

  公开号：US20060004017A1

  公开（公告）日：2006-01-05

  The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is —O—, —NH—, —S—, —CH 2 — or a direct bond; n is 0-5; m is 0-3; R 2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylsulphanyl, —NR 3 R 4 (wherein R 3 and R 4 , which may be the same or different, each represents hydrogen or C 1-3 alkyl), or R 5 X t — (wherein X 1 and R 5 are as defined herein; R 1 represents hydrogen, oxo, halogeno, hydroxy, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 alkoxymethyl, C 1-4 alkanoyl, C 1-4 haloalkyl, cyano, amino, C 2-5 alkenyl, C 2-5 alkynyl, C 1-3 alkanoyloxy, nitro, C 1-4 alkanoylamino, C 1-4 alkoxycarbonyl, C 1-4 alkylsulphanyl, C 1-4 alkylsulphinyl, C 1-4 alkylsulphonyl, carbamoyl, N —C 1-4 alkylcarbamoyl, N,N -di(C 1-4 alkyl)carbamoyl, aminosulphonyl, N —C 1-4 alkylaminosulphonyl, N,N -di(C 1-4 alkyl)aminosulphonyl, N -(C 1-4 alkylsulphonyl)amino, N —(C 1-4 alkylsulphonyl)— N —(C 1-4 alkyl)amino, N,N -di(C 1-4 alkylsulphonyl)amino, a C 3-7 alkylene chain joined to two ring C carbon atoms, C 1-4 alkanoylaminoC 1-4 alkyl, carboxy or a group R 56 X 10 (wherein X 10 and R 56 are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及使用公式（I）的化合物，其中环C是一个包含1-3个独立选择的杂原子O、N和S的8、9、10、12或13元双环或三环基团；Z是-O-、-NH-、-S-、-CH2-或直接键；n为0-5；m为0-3；R2表示氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、-NR3R4（其中R3和R4，可以相同，也可以不同，分别表示氢或C1-3烷基），或R5Xt-（其中X1和R5如上定义）；R1表示氢、酮、卤代、羟基、C1-4烷氧基、C1-4烷基、C1-4烷氧甲基、C1-4酰基、C1-4卤代烷基、氰基、氨基、C2-5烯基、C2-5炔基、C1-3酰氧基、硝基、C1-4酰胺基、C1-4烷氧羰基、C1-4烷基硫基、C1-4烷基亚硫基、C1-4烷基磺酰基、氨基甲酰基、N-C1-4烷基氨基甲酰基、N，N-二（C1-4烷基）氨基甲酰基、氨基磺酰基、N-C1-4烷基氨基磺酰基、N，N-二（C1-4烷基）氨基磺酰基、N-（C1-4烷基磺酰基）氨基、N-（C1-4烷基磺酰基）-N-（C1-4烷基）氨基、N，N-二（C1-4烷基磺酰基）氨基、连接两个环C碳原子的C3-7烷基链、C1-4酰胺基C1-4烷基、羧基或R56X10基团（其中X10和R56如上定义）；以及其盐，在制造用于产生在温血动物中的抗血管生成和/或血管通透性减少效应的药物中使用，制备这种化合物的方法，含有公式（I）的化合物或其药学上可接受的盐作为活性成分的制药组合物和公式（I）的化合物。公式（I）的化合物及其药学上可接受的盐抑制VEGF的效果，在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值。
• Catalyst for production of a polyurethane resin and method for producing a polyurethane resin
  申请人：——

  公开号：US20030088046A1

  公开（公告）日：2003-05-08

  Polyurethane resins are produced by reacting a polyol with a polyisocyanate in the presence of an amine catalyst of one of the formulae: 1

  聚氨酯树脂是通过在一种胺催化剂的存在下，将聚醇与聚异氰酸酯反应而制得的，该胺催化剂的化学式之一为：1
• Catalyst for production of a polyurethane resin and method for producting a polyurethane resin
  申请人：Tosoh Corporation

  公开号：US20040147705A1

  公开（公告）日：2004-07-29

  A method for producing a polyurethane resin, which comprises reacting a polyol with a polyisocyanate in the presence of a catalyst selected from the group consisting of a catalyst (A) containing an amine compound of the following formula (1): 1 wherein each of R 1 and R 2 which are independent of each other, is a C 1-4 alkyl group, and A is a C 5-10 straight chain or branched chain alkylene group; a catalyst (B) containing an amine compound of the following formula (2): 2 a catalyst (C) containing an amine compound of the following formula (3): 3 a catalyst (D) containing a compound of the following formula (5): 4 wherein each of R 3 , R 4 and R 5 which are independent of one another, is a hydrogen atom or a C 1-4 alkyl group, R 6 is a hydrogen atom, a functional group of the following formula: 5 wherein R 7 is a hydrogen atom or a C 1-4 alkyl group, and p is an integer of from 1 to 3, or a 3-aminopropyl group, and an amine compound of the following formula (6): 6 wherein X is a nitrogen atom or an oxygen atom, each of R 8 and R 9 which are independent of each other, is a methyl group or a functional group of the following formula: 7 wherein R 10 is a hydrogen atom or a C 1-4 alkyl group, and q is an integer of from 1 to 3, and each of m and n is an integer of from 1 to 2, provided that when X is a nitrogen atom, R 8 and R 9 are not simultaneously methyl groups, and that when X is an oxygen atom, R 9 is a functional group of the following formula: 8 wherein R 10 is a hydrogen atom or a C 1-4 alkyl group, and q is an integer of from 1 to 3; and a catalyst (E) containing an amine compound of the following formula (7): 9 wherein each of R 11 , R 12 and R 13 which are independent of one another, is a hydrogen atom or a C 1-4 straight chain or branched chain alkyl group, and R 14 is a C 1-4 straight chain or branched chain alkylene group.

  一种制备聚氨酯树脂的方法，其包括在催化剂的存在下，将聚醇与聚异氰酸酯反应，所述催化剂从以下组中选择：催化剂（A）包含以下公式（1）的胺化合物：其中，R1和R2各自独立地是C1-4烷基，A是C5-10直链或支链烷基；催化剂（B）包含以下公式（2）的胺化合物：催化剂（C）包含以下公式（3）的胺化合物：催化剂（D）包含以下公式（5）的化合物：其中，R3、R4和R5各自独立地是氢原子或C1-4烷基，R6是氢原子，以下式子的功能基：其中，R7是氢原子或C1-4烷基，p是1到3之间的整数，或3-氨丙基基团，以及以下公式（6）的胺化合物：其中，X是氮原子或氧原子，R8和R9各自独立地是甲基或以下式子的功能基：其中，R10是氢原子或C1-4烷基，q是1到3之间的整数，m和n各自是1到2之间的整数，但当X是氮原子时，R8和R9不能同时为甲基，当X是氧原子时，R9是以下式子的功能基：其中，R10是氢原子或C1-4烷基，q是1到3之间的整数；以及催化剂（E）包含以下公式（7）的胺化合物：其中，R11、R12和R13各自独立地是氢原子或C1-4直链或支链烷基，R14是C1-4直链或支链烷基。